MarketWatch

Vivacelle Bio Enrolls First Patient in Phase 3 Trial of Hypovolemia Due to Septic Shock for Phospholipid Nanoparticle-Based VBI-S

Septic shock results in approximately 350,000 deaths in the U.S. each year, the leading cause of hospital-related mortality and a major financial burden for the medical system Six trial sites with ...
Business Wire

Vivacelle Bio’s VBI-S Phase IIa Clinical Trial Meets Primary and Secondary Endpoints for Treating Hypovolemia in Septic Shock Patients

KANSAS CITY, Mo.--(BUSINESS WIRE)--Vivacelle Bio, Inc., a privately held life science company focused on the development of treatments for hypovolemia in shock including septic shock and hemorrhagic ...
KTLA

Vivacelle Bio's VBI-S Phase IIa Clinical Trial Meets Primary and Secondary Endpoints for Treating Hypovolemia in Septic Shock Patients

KANSAS CITY, Mo., Feb. 10, 2023 /PRNewswire/ -- Vivacelle Bio, Inc., a privately held life science company focused on the development of treatments for hypovolemia in shock including septic shock and ...